This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Scopolamine-n-butylbromide cartel occurred over at least 30 years, CADE says

By Ana Paula Candil ( November 22, 2021, 20:37 GMT | Insight) -- An international cartel involving pharmaceutical ingredient scopolamine-n-butylbromide (SnBB), with "possible" effects in Brazil, took place for "at least" 30 years, from 1989 to 2019 — one of the longest-running cartels investigated by the Brazilian competition authority. The Administrative Council for Economic Defense on Friday opened a formal investigation into seven pharmaceutical companies including Alchem International Pvt and Boehringer Ingelheim Pharma GmbH & Co. KG.An international cartel involving pharmaceutical ingredient scopolamine-n-butylbromide (SnBB), with "possible" effects in Brazil, took place for "at least" 30 years, from 1989 to 2019 — one of the longest-running cartels investigated by the Brazilian competition authority. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections